Keyword: Eli Lilly

Lilly commited $820 million in development milestones for the chance to work with Sitryx on drugs that manipulate intracellular metabolic pathways.

Companies including Novartis and Pfizer are contributing to the joint response through actions including the sharing of proprietary compounds

The action sees Pfizer join Bristol Myers Squibb and Eli Lilly on the list of Big Pharma companies to revise their R&D plans.

Eli Lilly detailed its plans to offer drive-through COVID-19 testing out of its Indianapolis headquarters—starting today for healthcare providers.

Lilly has decided to delay most trial starts and pause enrollment in most ongoing studies to ease the burden on healthcare systems.

The FierceBiotech roundup of the biopharma industry's treatment approach to COVID-19.

Eli Lilly is opening the doors of its Indianapolis headquarters to help the state health department process COVID-19 samples.

Provention Bio hit the brakes on elements of a phase 3 study for its diabetes treatment “out of an abundance of caution.”

Sigilon raised $80.3 million to advance its encapsulated cell treatments, including a treatment for hemophilia A.

The partners aim to have an antibody in the clinic within four months, giving them a shot at contributing to efforts to counter the virus.